Cardiome Pharma Corp. today announced that it has been advised by its partner, Merck (known as MSD outside the United States and Canada), that the current review of vernakalant (oral) is complete, and that Merck has informed Cardiome of its next steps in clinical development for vernakalant (oral) beginning in 2011.
“We are delighted that Merck has confirmed its plans for development of vernakalant (oral), and we look forward to working with them as they advance the vernakalant (oral) program to maximize its full potential,” said Doug Janzen, Chief Executive Officer and President of Cardiome.
Merck Cardiome Agreement
In April 2009, Cardiome and Merck announced a collaboration and license agreement for the development and commercialization of vernakalant. The agreement provides Merck Sharp and Dohme Corp. (formerly known as Merck & Co., Inc.) with exclusive global rights to vernakalant oral formulation for the maintenance of normal heart rhythm in patients with atrial fibrillation (AF), and provides another Merck affiliate, Merck Sharp & Dohme (Switzerland) GmbH, with exclusive rights outside of the United States, Canada and Mexico to vernakalant IV formulation for rapid conversion of recent onset AF to sinus rhythm in adults.
Source: CARDIOME PHARMA CORP.